flutiform offers sustained anti-inflammatory power1
Fluticasone propionate is a potent corticosteroid with sustained anti-inflammatory activity.1–3 It binds to glucocorticoid receptors within cells and decreases the release of inflammatory mediators from immune cells.4
flutiform helps reduce asthma exacerbations5
flutiform significantly reduces asthma exacerbations* vs. fluticasone propionate.5 In addition, two open-label, long-term studies† showed that only 2.1% of patients taking flutiform experienced an exacerbation requiring oral corticosteroids.6
*Exacerbation defined as peak expiratory flow rate >30% below baseline ≥2 consecutive days, awakening at night due to asthma ≥2 consecutive days, rescue medication use at least 4–5 times/day ≥2 consecutive days, deterioration in asthma necessitating additional therapy, or emergency visit/hospitalisation due to asthma.
†n=752 patients, Study 1: 60 weeks, Study 2: up to 52 weeks duration. Pooled analysis.
1. flutiform Summary of Product Characteristics 2015. 2. Mager DE et al. Pharm Sci. 2003; 92: 1521–1525. 3. Johnson M. J Allergy Clin Immunol. 1998; 101(4): S434–S439. 4. Barnes PJ. British Journal of Pharmacology. 2006; 148(3): 245–254. 5. Papi A et al. Respir Med. 2015; 109(2): 208–217. 6. Papi A et al. J Aerosol Med Pulm Drug Deliv. 2016: 29; 346-361.